J Addict Med. 2020 Jan 14. doi: 10.1097 / ADM.0000000000000602.
Yazi K1, UFuchs-Leitner I, UGerstgrasser NW.
abstract
I-mu-opioid antagonist nalmefene (18 mg ngosuku) yayiphathwa ekwelashweni kowesilisa ongathandani nabesifazane abebengumlutha we-inthanethi wezithombe zobulili ezingcolile. Isiguli besingenakho okunye ukulutha noma ama-comorbidities wezengqondo, sivumele isilinganiso esiqondile sokusebenza kwe-nalmefene ekulutha kwezocansi kwe-inthanethi. Esikhathini esingamaviki angama-72 nobuningi bokuhlola phakathi kwamasonto ayi-1 no-18, ukuhlola okuzihlola kokusebenzisa izinkanuko nokusebenzisa izithombe zobulili ezingcolile kwaqoqelwa ezikhaleni ezihlukile zokukhanuka kanye nezilinganiso eziphoqayo. Imiphumela ikhombisa ukuthi i-nalmefene izinciphise ngokumangazayo izimpawu zomlutha. Ngokubalulekile, ukwahlukaniswa okwenziwe yisineke kwe-nalmefene kuholele ekukhuphuleni ngokushesha kwezikolo ezifisayo kanye nokuziphatha okuluthayo, okubuye kwehle futhi ngemuva kokuqala kabusha umuthi. Isiguli besilokhu sithethelela ngokuphelele izimpawu zesikhathi esingaphezu konyaka sisigadli, nangeminye iminyaka engu-2 ngemuva kwalokho ngokusho kwe-akhawunti yakhe. Ngakho-ke, i-nalmefene ibonakala iyisihlanganisi esisebenzayo seziguli ezinomlutha wezocansi we-inthanethi.
I-PMID: 31972764
;